Identification

Name
Apalutamide
Accession Number
DB11901
Type
Small Molecule
Groups
Approved, Investigational
Description

Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements [1]. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors [1]. In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of Bicalutamide or Enzalutamide. Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines [1].

Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males [2]. Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [3]. Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [1]. In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [1]. In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo [3]. Apalutamide displayed good tolerability and safety profile in clinical studies.

Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer [3].

Structure
Thumb
Synonyms
Not Available
External IDs
JNJ-56021927
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ErleadaTablet, film coated60 mg/1OralJanssen, Lp2018-02-14Not applicableUs
Categories
UNII
4T36H88UA7
CAS number
956104-40-8
Weight
Average: 477.44
Monoisotopic: 477.088258569
Chemical Formula
C21H15F4N5O2S
InChI Key
HJBWBFZLDZWPHF-UHFFFAOYSA-N
InChI
InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)
IUPAC Name
4-{7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl}-2-fluoro-N-methylbenzamide
SMILES
CNC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C11CCC1)C1=CC(=C(N=C1)C#N)C(F)(F)F

Pharmacology

Indication

Indicated for the treatment of patients with non-metastatic, castration-resistant prostate cancer (NM-CRPC) [FDA Label].

Structured Indications
Pharmacodynamics

In an open-label, uncontrolled, multi-center, single-arm dedicated QT study in 45 patients with CRPC, an exposure-QT analysis suggested a concentration-dependent increase in QTcF for apalutamide and its active metabolite. Apalutamide demonstrated an antitumor activity in the mouse xenograft models of prostate cancer, where it decreased tumor cell proliferation and reduced tumor volume [FDA Label].

Mechanism of action

Persistent androgen receptor (AR) signaling is a common feature of castration-resistant prostate cancer (CRPC), attributed to AR gene-amplification, AR gene mutation, increased AR expression or increased androgen biosynthesis in prostate tumors [2]. Apalutamide is an antagonist of AR that to the binding-site in the ligand-binding domain of the receptor with the IC50 of 16 nM. Upon binding, apalutamide disrupts AR signalling, inhibits DNA binding, and impedes AR-mediated gene transcription [FDA Label]. Apalutamide impairs the translocation of AR from the cytoplasm to the nucleus thus reduces the concentrations of AR available to interact with the androgen response-elements (AREs) [2]. Upon treatment with apalutamide, AR was not recruited to the DNA promoter-regions [2].

Its main metabolite, N-desmethyl apalutamide, is a less potent inhibitor of AR, and exhibited one-third the activity of apalutamide in an in vitro transcriptional reporter assay [FDA Label].

TargetActionsOrganism
AAndrogen receptor
antagonist
Human
UGABA-A receptor (anion channel)
antagonist
Human
Absorption

Mean absolute oral bioavailability was approximately 100%. Median time to achieve peak plasma concentration (tmax) was 2 hours (range: 1 to 5 hours). Median tmax may be increased with a high-fat meal. Administration of oral apalutamide at recommended dosages resulted in a steady state within 4 weeks with a maximum peak concentration (Cmax) and AUC of 6.0 mcg/mL and 100 mcg·h/mL, respectively [FDA Label]. Cmax and AUC of apalutamide is expected to increase in a dose-proportional manner. The mean mean peak-to-trough ratio was 1.63 indicating low daily fluctuations in the plasma concentrations of the drug.

The major active metabolite N-desmethyl apalutamide Cmax was 5.9 mcg/mL (1.0) and AUC was 124 mcg·h/mL (23) at steady-state after the recommended dosage.

Volume of distribution

The mean apparent volume of distribution at steady-state of apalutamide was approximately 276 L [FDA Label].

Protein binding

Apalutamide was 96% and N-desmethyl apalutamide was 95% bound to plasma proteins with no concentration dependency [FDA Label].

Metabolism

Apalutamide primarily undergoes CYP2C8 and CYP3A4-mediated metabolism to its pharmacologically active metabolite, N-desmethyl apalutamide. The contribution of CYP2C8 and CYP3A4 in the total metabolism of apalutamide is approximately 58% and and 13% following single dose but changes to 40% and 37%, respectively at steady-state [FDA Label]. The auto-induction of CYP3A4-mediated metabolism by apalutamide may explain the increase in CYP3A4 enzymatic activity at steady-state.

Based on systemic exposure, relative potency, and pharmacokinetic properties, N-desmethyl apalutamide likely contributed to the clinical activity of apalutamide [FDA Label].

Route of elimination

Apalutamide and its main active metabolite are subject to both renal and focal elimination. Up to 70 days following a single oral administration of radiolabeled apalutamide, 65% of the dose was recovered in urine (1.2% of dose as unchanged apalutamide and 2.7% as N-desmethyl apalutamide) and 24% was recovered in feces (1.5% of dose as unchanged apalutamide and 2% as N-desmethyl apalutamide) [FDA Label].

Half life

The mean effective half-life for apalutamide in patients with NM-CRPC was approximately 3 days at steady-state [FDA Label].

Clearance

The CL/F of apalutamide was 1.3 L/h after single dosing and increased to 2.0 L/h at steady-state after once-daily dosing. An increase in apparent clearance (CL/F) was observed with repeat dosing, likely due to induction of apalutamide’s own metabolism. The auto-induction effect likely reached its maximum at the recommended dosage because exposure of apalutamide across the dose range of 30 to 480 mg is dose-proportional [FDA Label].

Toxicity

There is no known specific antidote for apalutamide overdose. In the event of an overdose, discontinue apalutamide and undertake general supportive measures until clinical toxicity has been diminished or resolved [FDA Label].

Apalutamide was not shown to be mutagenic in the bacterial reverse mutation (Ames) assay and was not genotoxic in either in vitro chromosome aberration assay or the in vivo rat bone marrow micronucleus assay or the in vivo rat Comet assay. The carcinogenic potential of the drug has not been evaluated. In repeat-dose toxicity studies in male rats and dogs, atrophy of the prostate gland and seminal vesicles, aspermia/hypospermia, tubular degeneration and/or hyperplasia or hypertrophy of the interstitial cells in the reproductive system were observed at doses 0.9-1.4 times the human exposure based on AUC [FDA Label]. In a fertility study of male rats, a decrease in sperm concentration and motility, increased abnormal sperm morphology, lower copulation and fertility rates in addition to reduced weights of the secondary sex glands and epididymis were observed following 4 weeks of dosing at ≥ 25 mg/kg/day [FDA Label].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Apalutamide.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Apalutamide.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be decreased when it is combined with Apalutamide.Experimental, Illicit
AbemaciclibThe serum concentration of Abemaciclib can be decreased when it is combined with Apalutamide.Approved, Investigational
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Apalutamide.Approved
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Apalutamide.Approved, Investigational
AceclofenacThe serum concentration of Aceclofenac can be decreased when it is combined with Apalutamide.Approved, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Apalutamide.Approved, Investigational
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Apalutamide.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Apalutamide.Approved, Vet Approved
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Apalutamide.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Apalutamide.Approved
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Apalutamide.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Apalutamide.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Apalutamide.Experimental, Investigational
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Apalutamide.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Apalutamide.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Apalutamide.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Apalutamide.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Apalutamide.Approved
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Apalutamide.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Apalutamide.Approved
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Apalutamide.Approved, Withdrawn
alpha-Tocopherol acetateThe serum concentration of alpha-Tocopherol acetate can be decreased when it is combined with Apalutamide.Approved
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Apalutamide.Approved, Illicit, Investigational
AlvocidibThe serum concentration of Alvocidib can be decreased when it is combined with Apalutamide.Experimental, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Apalutamide.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Apalutamide.Approved, Investigational
AmcinonideThe serum concentration of Amcinonide can be decreased when it is combined with Apalutamide.Approved
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Apalutamide.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Apalutamide.Approved
AmiodaroneThe serum concentration of Apalutamide can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Apalutamide.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Apalutamide.Approved
AmoxicillinThe serum concentration of Amoxicillin can be decreased when it is combined with Apalutamide.Approved, Vet Approved
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Apalutamide.Approved, Investigational
AndrostenedioneThe serum concentration of Androstenedione can be decreased when it is combined with Apalutamide.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be decreased when it is combined with Apalutamide.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be decreased when it is combined with Apalutamide.Investigational
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Apalutamide.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Apalutamide.Approved, Investigational
Arachidonic AcidThe serum concentration of Arachidonic Acid can be decreased when it is combined with Apalutamide.Experimental
ArformoterolThe serum concentration of Arformoterol can be decreased when it is combined with Apalutamide.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Apalutamide.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Apalutamide.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Apalutamide.Approved, Investigational
ArtemetherThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Apalutamide resulting in a loss in efficacy.Approved
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Apalutamide.Approved
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Apalutamide.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Apalutamide.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
AtamestaneThe serum concentration of Atamestane can be decreased when it is combined with Apalutamide.Investigational
AtazanavirThe serum concentration of Apalutamide can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Apalutamide.Approved
AtomoxetineThe serum concentration of Atomoxetine can be decreased when it is combined with Apalutamide.Approved
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Apalutamide.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Apalutamide.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Apalutamide.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Apalutamide.Approved
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Apalutamide.Approved
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Apalutamide.Investigational
BaricitinibThe serum concentration of Baricitinib can be decreased when it is combined with Apalutamide.Approved, Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Apalutamide.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Apalutamide.Approved
BelinostatThe serum concentration of Belinostat can be decreased when it is combined with Apalutamide.Approved, Investigational
BenidipineThe serum concentration of Benidipine can be decreased when it is combined with Apalutamide.Approved, Investigational
BenzatropineThe serum concentration of Benzatropine can be decreased when it is combined with Apalutamide.Approved
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Apalutamide.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Apalutamide.Approved
BenzylpenicillinThe serum concentration of Benzylpenicillin can be decreased when it is combined with Apalutamide.Approved, Vet Approved
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Apalutamide.Approved, Vet Approved
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Apalutamide.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Apalutamide.Approved, Investigational
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Apalutamide.Approved
BictegravirThe serum concentration of Bictegravir can be decreased when it is combined with Apalutamide.Approved, Investigational
BioallethrinThe serum concentration of Bioallethrin can be decreased when it is combined with Apalutamide.Approved, Experimental
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Apalutamide.Approved
BlonanserinThe serum concentration of Blonanserin can be decreased when it is combined with Apalutamide.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Apalutamide.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Apalutamide.Approved, Investigational
BosentanThe serum concentration of Bosentan can be decreased when it is combined with Apalutamide.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Apalutamide.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Apalutamide.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Apalutamide.Approved, Investigational
BrigatinibThe serum concentration of Brigatinib can be decreased when it is combined with Apalutamide.Approved, Investigational
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Apalutamide.Approved
BrivaracetamThe serum concentration of Brivaracetam can be decreased when it is combined with Apalutamide.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Apalutamide.Approved, Illicit, Investigational
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Apalutamide.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Apalutamide.Approved
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Apalutamide.Approved
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Apalutamide.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Apalutamide.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Apalutamide.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Apalutamide.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Apalutamide.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Apalutamide.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Apalutamide.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Apalutamide.Approved, Investigational
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Apalutamide.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Apalutamide.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Apalutamide.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Apalutamide.Approved
CandesartanThe serum concentration of Candesartan can be decreased when it is combined with Apalutamide.Experimental
Candesartan cilexetilThe serum concentration of Candesartan cilexetil can be decreased when it is combined with Apalutamide.Approved
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Apalutamide.Approved, Investigational
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Apalutamide.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Apalutamide.Approved
CarboplatinThe serum concentration of Carboplatin can be decreased when it is combined with Apalutamide.Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Apalutamide.Approved, Investigational
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Apalutamide.Approved, Investigational
CarisoprodolThe serum concentration of Carisoprodol can be decreased when it is combined with Apalutamide.Approved
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Apalutamide.Approved, Investigational
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Apalutamide.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Apalutamide.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Apalutamide.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Apalutamide.Approved, Withdrawn
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Apalutamide.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Apalutamide.Approved
ChloramphenicolThe serum concentration of Chloramphenicol can be decreased when it is combined with Apalutamide.Approved, Vet Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Apalutamide.Approved, Illicit, Investigational
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Apalutamide.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
ChlorpropamideThe serum concentration of Chlorpropamide can be decreased when it is combined with Apalutamide.Approved, Investigational
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Apalutamide.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Apalutamide.Approved, Nutraceutical
CholesterolThe serum concentration of Cholesterol can be decreased when it is combined with Apalutamide.Approved, Experimental, Investigational
Cholic AcidThe serum concentration of Cholic Acid can be decreased when it is combined with Apalutamide.Approved
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Apalutamide.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Apalutamide.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Apalutamide.Approved, Investigational
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Apalutamide.Approved
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Apalutamide.Approved, Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Apalutamide.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Apalutamide.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Apalutamide.Approved
CladribineThe serum concentration of Cladribine can be decreased when it is combined with Apalutamide.Approved, Investigational
ClarithromycinThe serum concentration of Apalutamide can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Apalutamide can be decreased when combined with Clemastine.Approved, Investigational
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Apalutamide.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Apalutamide.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be decreased when it is combined with Apalutamide.Approved, Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be decreased when it is combined with Apalutamide.Approved
ClobetasoneThe serum concentration of Clobetasone can be decreased when it is combined with Apalutamide.Approved
ClocortoloneThe serum concentration of Clocortolone can be decreased when it is combined with Apalutamide.Approved
ClofarabineThe serum concentration of Clofarabine can be decreased when it is combined with Apalutamide.Approved, Investigational
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Apalutamide.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Apalutamide.Approved, Investigational
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Apalutamide.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Apalutamide.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Apalutamide.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Apalutamide.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Apalutamide.Approved
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Apalutamide.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Apalutamide.Approved, Illicit
ClotrimazoleThe metabolism of Apalutamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Apalutamide.Approved
CobicistatThe serum concentration of Apalutamide can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Apalutamide.Approved, Investigational
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Apalutamide.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Apalutamide.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Apalutamide.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Apalutamide.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Apalutamide.Approved
CopanlisibThe serum concentration of Copanlisib can be decreased when it is combined with Apalutamide.Approved, Investigational
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be decreased when it is combined with Apalutamide.Investigational
CorticosteroneThe serum concentration of Corticosterone can be decreased when it is combined with Apalutamide.Experimental
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Apalutamide.Approved, Investigational
CrisaboroleThe metabolism of Apalutamide can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Apalutamide.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Apalutamide.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Apalutamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Apalutamide.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Apalutamide.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Apalutamide.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Apalutamide.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Apalutamide.Approved, Investigational
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Apalutamide.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Apalutamide.Approved
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Apalutamide.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Apalutamide.Approved, Investigational
DarunavirThe serum concentration of Apalutamide can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Apalutamide.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Apalutamide.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Apalutamide.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Apalutamide.Approved, Investigational
DeferasiroxThe serum concentration of Apalutamide can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe serum concentration of Deflazacort can be decreased when it is combined with Apalutamide.Approved, Investigational
DelafloxacinThe serum concentration of Delafloxacin can be decreased when it is combined with Apalutamide.Approved, Investigational
DelamanidThe serum concentration of Delamanid can be decreased when it is combined with Apalutamide.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Apalutamide.Approved
DesipramineThe serum concentration of Desipramine can be decreased when it is combined with Apalutamide.Approved, Investigational
DesonideThe serum concentration of Desonide can be decreased when it is combined with Apalutamide.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be decreased when it is combined with Apalutamide.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Apalutamide.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Apalutamide.Experimental, Vet Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Apalutamide.Approved, Investigational
DeutetrabenazineThe serum concentration of Deutetrabenazine can be decreased when it is combined with Apalutamide.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Apalutamide.Vet Approved
Dexchlorpheniramine maleateThe serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Apalutamide.Approved
DexlansoprazoleThe serum concentration of Dexlansoprazole can be decreased when it is combined with Apalutamide.Approved, Investigational
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Apalutamide.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Apalutamide.Approved, Illicit, Investigational, Withdrawn
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Apalutamide.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Apalutamide.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be decreased when it is combined with Apalutamide.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Apalutamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Apalutamide.Approved, Investigational
DiflorasoneThe serum concentration of Diflorasone can be decreased when it is combined with Apalutamide.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be decreased when it is combined with Apalutamide.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Apalutamide.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Apalutamide.Approved
Dihydro-alpha-ergocryptineThe serum concentration of Dihydro-alpha-ergocryptine can be decreased when it is combined with Apalutamide.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Apalutamide.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Apalutamide.Approved, Investigational
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Apalutamide.Approved, Investigational
DinoprostoneThe serum concentration of Dinoprostone can be decreased when it is combined with Apalutamide.Approved
DiphenhydramineThe serum concentration of Diphenhydramine can be decreased when it is combined with Apalutamide.Approved, Investigational
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Apalutamide.Approved
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Apalutamide.Approved
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Apalutamide.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Apalutamide.Approved, Investigational
DoconexentThe serum concentration of Doconexent can be decreased when it is combined with Apalutamide.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Apalutamide.Approved, Investigational
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Apalutamide.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Apalutamide.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Apalutamide.Approved
DopamineThe serum concentration of Dopamine can be decreased when it is combined with Apalutamide.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Apalutamide.Approved
DoxazosinThe serum concentration of Doxazosin can be decreased when it is combined with Apalutamide.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Apalutamide.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Apalutamide.Approved, Investigational
DoxycyclineThe metabolism of Apalutamide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Apalutamide.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Apalutamide.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Apalutamide.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Apalutamide.Approved
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Apalutamide.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be decreased when it is combined with Apalutamide.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Apalutamide.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Apalutamide.Approved
EluxadolineThe serum concentration of Eluxadoline can be decreased when it is combined with Apalutamide.Approved, Investigational
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Apalutamide.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Apalutamide.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Apalutamide.Approved, Investigational
EnfuvirtideThe serum concentration of Enfuvirtide can be decreased when it is combined with Apalutamide.Approved, Investigational
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Apalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Apalutamide.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Apalutamide.Approved
EpoprostenolThe serum concentration of Epoprostenol can be decreased when it is combined with Apalutamide.Approved
EquileninThe serum concentration of Equilenin can be decreased when it is combined with Apalutamide.Experimental
EquilinThe serum concentration of Equilin can be decreased when it is combined with Apalutamide.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Apalutamide.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Apalutamide.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Apalutamide.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Apalutamide.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Apalutamide.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be decreased when it is combined with Apalutamide.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Apalutamide.Approved, Investigational
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Apalutamide.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Apalutamide.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Apalutamide.Approved, Investigational
EstriolThe serum concentration of Estriol can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Apalutamide.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Apalutamide.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Apalutamide.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Apalutamide.Approved, Investigational
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Apalutamide.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Apalutamide.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Apalutamide.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Apalutamide.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be decreased when it is combined with Apalutamide.Approved
EtodolacThe serum concentration of Etodolac can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Apalutamide.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Apalutamide.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Apalutamide.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Apalutamide.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Apalutamide.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Apalutamide.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Apalutamide.Approved
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Apalutamide.Approved, Investigational
FamotidineThe serum concentration of Famotidine can be decreased when it is combined with Apalutamide.Approved
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Apalutamide.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Apalutamide.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Apalutamide.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Apalutamide.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Apalutamide.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Apalutamide.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Apalutamide.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Apalutamide.Approved
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Apalutamide.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Apalutamide.Approved, Investigational
FluasteroneThe serum concentration of Fluasterone can be decreased when it is combined with Apalutamide.Investigational
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be decreased when it is combined with Apalutamide.Approved
FluconazoleThe metabolism of Apalutamide can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Apalutamide.Approved, Investigational
FlumethasoneThe serum concentration of Flumethasone can be decreased when it is combined with Apalutamide.Approved, Vet Approved
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Apalutamide.Approved
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Apalutamide.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Apalutamide.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be decreased when it is combined with Apalutamide.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be decreased when it is combined with Apalutamide.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Apalutamide.Approved, Investigational
FluorouracilThe serum concentration of Fluorouracil can be decreased when it is combined with Apalutamide.Approved
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Apalutamide.Approved, Vet Approved
FluprednideneThe serum concentration of Fluprednidene can be decreased when it is combined with Apalutamide.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be decreased when it is combined with Apalutamide.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be decreased when it is combined with Apalutamide.Approved
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Apalutamide.Approved, Illicit, Investigational
FlurbiprofenThe serum concentration of Flurbiprofen can be decreased when it is combined with Apalutamide.Approved, Investigational
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Apalutamide.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Apalutamide.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be decreased when it is combined with Apalutamide.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Apalutamide.Approved
FluvoxamineThe metabolism of Apalutamide can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe serum concentration of Folic Acid can be decreased when it is combined with Apalutamide.Approved, Nutraceutical, Vet Approved
FormestaneThe serum concentration of Formestane can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
FormoterolThe serum concentration of Formoterol can be decreased when it is combined with Apalutamide.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Apalutamide.Approved
FosaprepitantThe serum concentration of Apalutamide can be increased when it is combined with Fosaprepitant.Approved
FosnetupitantThe serum concentration of Fosnetupitant can be decreased when it is combined with Apalutamide.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be decreased when it is combined with Apalutamide.Approved, Investigational
FostamatinibThe serum concentration of Fostamatinib can be decreased when it is combined with Apalutamide.Approved, Investigational
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Apalutamide.Approved, Investigational
Fusidic AcidThe serum concentration of Apalutamide can be increased when it is combined with Fusidic Acid.Approved, Investigational
Gadoxetic acidThe serum concentration of Gadoxetic acid can be decreased when it is combined with Apalutamide.Approved
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Apalutamide.Approved
GavestinelThe serum concentration of Gavestinel can be decreased when it is combined with Apalutamide.Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Apalutamide.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Apalutamide.Approved
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Apalutamide.Approved
GimatecanThe serum concentration of Gimatecan can be decreased when it is combined with Apalutamide.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be decreased when it is combined with Apalutamide.Approved, Investigational
GliclazideThe serum concentration of Gliclazide can be decreased when it is combined with Apalutamide.Approved
GlimepirideThe serum concentration of Glimepiride can be decreased when it is combined with Apalutamide.Approved
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Apalutamide.Approved, Investigational
GlucosamineThe serum concentration of Glucosamine can be decreased when it is combined with Apalutamide.Approved, Investigational
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Apalutamide.Approved
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Apalutamide.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Apalutamide.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Apalutamide.Approved, Investigational
HalcinonideThe serum concentration of Halcinonide can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Apalutamide.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Apalutamide.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Apalutamide.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be decreased when it is combined with Apalutamide.Investigational
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Apalutamide.Approved
HistamineThe serum concentration of Histamine can be decreased when it is combined with Apalutamide.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Apalutamide.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Apalutamide.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Apalutamide.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Apalutamide.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Apalutamide.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Apalutamide.Approved
IcotinibThe serum concentration of Icotinib can be decreased when it is combined with Apalutamide.Approved, Investigational
IdarubicinThe serum concentration of Idarubicin can be decreased when it is combined with Apalutamide.Approved
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Apalutamide.Approved
IfosfamideThe serum concentration of Ifosfamide can be decreased when it is combined with Apalutamide.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Apalutamide.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Apalutamide.Approved
ImidafenacinThe serum concentration of Imidafenacin can be decreased when it is combined with Apalutamide.Approved, Investigational
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Apalutamide.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Apalutamide.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Apalutamide.Approved
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Apalutamide.Approved
IndinavirThe serum concentration of Apalutamide can be increased when it is combined with Indinavir.Approved
IndisulamThe serum concentration of Indisulam can be decreased when it is combined with Apalutamide.Investigational
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Apalutamide.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Apalutamide.Approved, Investigational
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Apalutamide.Approved
IrbesartanThe serum concentration of Irbesartan can be decreased when it is combined with Apalutamide.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Apalutamide.Approved, Investigational
IsavuconazoleThe serum concentration of Isavuconazole can be decreased when it is combined with Apalutamide.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Apalutamide resulting in a loss in efficacy.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Apalutamide.Approved, Investigational
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Apalutamide.Approved
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Apalutamide.Approved, Investigational
IstaroximeThe serum concentration of Istaroxime can be decreased when it is combined with Apalutamide.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Apalutamide.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Apalutamide.Approved
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Apalutamide.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Apalutamide.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Apalutamide.Approved, Investigational
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Apalutamide.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Apalutamide.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Apalutamide.Approved, Investigational
KetoconazoleThe serum concentration of Apalutamide can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe serum concentration of Ketoprofen can be decreased when it is combined with Apalutamide.Approved, Vet Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Apalutamide.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Apalutamide.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Apalutamide.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Apalutamide.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Apalutamide.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Apalutamide.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Apalutamide.Approved
LeflunomideThe serum concentration of Leflunomide can be decreased when it is combined with Apalutamide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Apalutamide.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Apalutamide.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Apalutamide.Approved, Investigational
LesinuradThe serum concentration of Lesinurad can be decreased when it is combined with Apalutamide.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be decreased when it is combined with Apalutamide.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Apalutamide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Apalutamide.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Apalutamide.Approved, Investigational
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Apalutamide.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Apalutamide.Approved, Investigational
LevomenolThe serum concentration of Levomenol can be decreased when it is combined with Apalutamide.Approved, Experimental
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Apalutamide.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Apalutamide.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Apalutamide.Approved, Investigational
LevosalbutamolThe serum concentration of Levosalbutamol can be decreased when it is combined with Apalutamide.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Apalutamide.Approved
LicofeloneThe serum concentration of Licofelone can be decreased when it is combined with Apalutamide.Investigational
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Apalutamide.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Apalutamide.Approved
LiothyronineThe serum concentration of Liothyronine can be decreased when it is combined with Apalutamide.Approved, Vet Approved
LiotrixThe serum concentration of Liotrix can be decreased when it is combined with Apalutamide.Approved
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Apalutamide.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Apalutamide.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Apalutamide.Approved
LopinavirThe serum concentration of Apalutamide can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Apalutamide.Approved, Investigational
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Apalutamide.Approved
LornoxicamThe serum concentration of Lornoxicam can be decreased when it is combined with Apalutamide.Approved, Investigational
LorpiprazoleThe serum concentration of Apalutamide can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Apalutamide.Approved
LoteprednolThe serum concentration of Loteprednol can be decreased when it is combined with Apalutamide.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Apalutamide.Approved, Investigational
LuliconazoleThe serum concentration of Apalutamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Apalutamide can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Apalutamide.Approved
LumiracoxibThe serum concentration of Lumiracoxib can be decreased when it is combined with Apalutamide.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Apalutamide.Approved, Investigational
MacimorelinThe serum concentration of Macimorelin can be decreased when it is combined with Apalutamide.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Apalutamide.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Apalutamide.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Apalutamide.Approved, Investigational
ME-609The serum concentration of ME-609 can be decreased when it is combined with Apalutamide.Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Apalutamide.Approved, Vet Approved
Medical CannabisThe serum concentration of Medical Cannabis can be decreased when it is combined with Apalutamide.Experimental, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Apalutamide.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be decreased when it is combined with Apalutamide.Approved
Mefenamic acidThe serum concentration of Mefenamic acid can be decreased when it is combined with Apalutamide.Approved
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Apalutamide.Approved, Investigational
MelatoninThe serum concentration of Melatonin can be decreased when it is combined with Apalutamide.Approved, Nutraceutical, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be decreased when it is combined with Apalutamide.Vet Approved
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Apalutamide.Approved, Vet Approved
MephenytoinThe serum concentration of Mephenytoin can be decreased when it is combined with Apalutamide.Investigational, Withdrawn
MeprobamateThe serum concentration of Meprobamate can be decreased when it is combined with Apalutamide.Approved, Illicit
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Apalutamide.Approved
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Apalutamide.Approved
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Apalutamide.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Apalutamide.Approved
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Apalutamide.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
MethsuximideThe serum concentration of Methsuximide can be decreased when it is combined with Apalutamide.Approved
MethylphenobarbitalThe serum concentration of Methylphenobarbital can be decreased when it is combined with Apalutamide.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Apalutamide.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Apalutamide.Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Apalutamide.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Apalutamide.Approved
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Apalutamide.Approved, Investigational
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Apalutamide.Approved, Investigational
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Apalutamide.Investigational, Withdrawn
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Apalutamide.Approved, Illicit
MidostaurinThe serum concentration of Midostaurin can be decreased when it is combined with Apalutamide.Approved, Investigational
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Apalutamide.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Apalutamide.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Apalutamide.Approved
MitotaneThe serum concentration of Apalutamide can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Apalutamide.Approved, Investigational
MoclobemideThe serum concentration of Moclobemide can be decreased when it is combined with Apalutamide.Approved, Investigational
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Apalutamide.Approved, Investigational
MometasoneThe serum concentration of Mometasone can be decreased when it is combined with Apalutamide.Approved, Vet Approved
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Apalutamide.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Apalutamide.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Apalutamide.Approved, Investigational
NabiloneThe metabolism of Apalutamide can be decreased when combined with Nabilone.Approved, Investigational
NabiximolsThe serum concentration of Nabiximols can be decreased when it is combined with Apalutamide.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Apalutamide.Approved
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Apalutamide.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Apalutamide.Approved, Vet Approved
NaproxenThe serum concentration of Naproxen can be decreased when it is combined with Apalutamide.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Apalutamide.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be decreased when it is combined with Apalutamide.Investigational
NefazodoneThe serum concentration of Apalutamide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Apalutamide can be increased when it is combined with Nelfinavir.Approved
NeratinibThe serum concentration of Neratinib can be decreased when it is combined with Apalutamide.Approved, Investigational
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Apalutamide.Approved, Investigational
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Apalutamide.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Apalutamide.Approved, Investigational
NiclosamideThe serum concentration of Niclosamide can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Apalutamide.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Apalutamide.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Apalutamide.Approved, Investigational
NilutamideThe serum concentration of Nilutamide can be decreased when it is combined with Apalutamide.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Apalutamide.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Apalutamide.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Apalutamide.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Apalutamide.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Apalutamide.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Apalutamide.Approved, Investigational
NitrofurantoinThe serum concentration of Nitrofurantoin can be decreased when it is combined with Apalutamide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Apalutamide.Approved
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Apalutamide.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Apalutamide.Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Apalutamide.Approved
OdanacatibThe serum concentration of Odanacatib can be decreased when it is combined with Apalutamide.Investigational
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Apalutamide.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Apalutamide.Approved
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Apalutamide.Investigational
OlmesartanThe serum concentration of Olmesartan can be decreased when it is combined with Apalutamide.Approved, Investigational
OlodaterolThe serum concentration of Olodaterol can be decreased when it is combined with Apalutamide.Approved
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Apalutamide.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Apalutamide.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Apalutamide.Approved
OpiumThe serum concentration of Opium can be decreased when it is combined with Apalutamide.Approved, Illicit
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Apalutamide.Approved
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Apalutamide.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Apalutamide.Approved, Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Apalutamide.Approved
OxaliplatinThe serum concentration of Oxaliplatin can be decreased when it is combined with Apalutamide.Approved, Investigational
OxaprozinThe serum concentration of Oxaprozin can be decreased when it is combined with Apalutamide.Approved
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Apalutamide.Approved
OxiconazoleThe serum concentration of Oxiconazole can be decreased when it is combined with Apalutamide.Approved
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Apalutamide.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Apalutamide.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Apalutamide.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Apalutamide.Approved, Investigational
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Apalutamide.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Apalutamide.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Apalutamide.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Apalutamide.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Apalutamide.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Apalutamide.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Apalutamide.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Apalutamide.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Apalutamide.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Apalutamide.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Apalutamide.Approved, Investigational
PentobarbitalThe serum concentration of Pentobarbital can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Apalutamide.Approved
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Apalutamide.Approved, Investigational
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Apalutamide.Approved, Investigational
PerospironeThe serum concentration of Perospirone can be decreased when it is combined with Apalutamide.Approved
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Apalutamide.Approved
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Apalutamide.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Apalutamide.Withdrawn
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Apalutamide.Approved, Investigational
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Apalutamide.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Apalutamide.Approved, Investigational
PhenylbutazoneThe serum concentration of Phenylbutazone can be decreased when it is combined with Apalutamide.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Apalutamide.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be decreased when it is combined with Apalutamide.Approved, Investigational
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Apalutamide.Approved, Investigational
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Apalutamide.Approved, Investigational
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Apalutamide.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Apalutamide.Approved
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Apalutamide.Approved, Investigational
PiperaquineThe serum concentration of Piperaquine can be decreased when it is combined with Apalutamide.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Apalutamide.Approved, Investigational
PiroxicamThe serum concentration of Piroxicam can be decreased when it is combined with Apalutamide.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Apalutamide.Approved
PitolisantThe serum concentration of Pitolisant can be decreased when it is combined with Apalutamide.Approved, Investigational
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Apalutamide.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Apalutamide.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Apalutamide.Approved, Investigational
PosaconazoleThe serum concentration of Apalutamide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Apalutamide.Approved, Investigational, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be decreased when it is combined with Apalutamide.Investigational
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Apalutamide.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Apalutamide.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Apalutamide.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Apalutamide.Approved
PrednicarbateThe serum concentration of Prednicarbate can be decreased when it is combined with Apalutamide.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Apalutamide.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Apalutamide.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be decreased when it is combined with Apalutamide.Approved, Experimental, Investigational
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Apalutamide.Approved
PrimidoneThe serum concentration of Primidone can be decreased when it is combined with Apalutamide.Approved, Vet Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Apalutamide.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Apalutamide.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Apalutamide.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Apalutamide.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Apalutamide.Approved
PropiverineThe serum concentration of Propiverine can be decreased when it is combined with Apalutamide.Approved, Investigational
PropofolThe serum concentration of Propofol can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe serum concentration of Propoxyphene napsylate can be decreased when it is combined with Apalutamide.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Apalutamide.Approved, Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Apalutamide.Approved, Investigational
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Apalutamide.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Apalutamide.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Apalutamide.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Apalutamide.Approved, Investigational
QuinineThe serum concentration of Quinine can be decreased when it is combined with Apalutamide.Approved
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Apalutamide.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Apalutamide.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Apalutamide.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Apalutamide.Approved
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Apalutamide.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Apalutamide.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Apalutamide.Approved
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Apalutamide.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Apalutamide.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Apalutamide.Approved
RibociclibThe serum concentration of Ribociclib can be decreased when it is combined with Apalutamide.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Apalutamide.Approved, Investigational
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Apalutamide.Approved
RifapentineThe metabolism of Apalutamide can be increased when combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Apalutamide.Approved
RiluzoleThe serum concentration of Riluzole can be decreased when it is combined with Apalutamide.Approved, Investigational
RimexoloneThe serum concentration of Rimexolone can be decreased when it is combined with Apalutamide.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Apalutamide.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Apalutamide.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Apalutamide.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Apalutamide.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Apalutamide.Approved
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
RoflumilastThe serum concentration of Roflumilast can be decreased when it is combined with Apalutamide.Approved
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Apalutamide.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Apalutamide.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Apalutamide.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Apalutamide.Approved
RosiglitazoneThe serum concentration of Rosiglitazone can be decreased when it is combined with Apalutamide.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Apalutamide.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Apalutamide.Approved
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Rucaparib can be decreased when it is combined with Apalutamide.Approved, Investigational
RupatadineThe serum concentration of Rupatadine can be decreased when it is combined with Apalutamide.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Apalutamide.Approved
SafinamideThe serum concentration of Safinamide can be decreased when it is combined with Apalutamide.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Apalutamide.Approved
SaquinavirThe serum concentration of Apalutamide can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Apalutamide can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Apalutamide.Approved
SecobarbitalThe metabolism of Apalutamide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Apalutamide.Approved
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Apalutamide.Approved
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Apalutamide.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Apalutamide.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Apalutamide.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Apalutamide.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Apalutamide.Approved
SiltuximabThe serum concentration of Apalutamide can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Apalutamide.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Apalutamide.Approved
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Apalutamide.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Apalutamide.Approved, Investigational
SitaxentanThe serum concentration of Sitaxentan can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Apalutamide.Approved
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Apalutamide.Approved
SomatostatinThe serum concentration of Somatostatin can be decreased when it is combined with Apalutamide.Approved, Investigational
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Apalutamide.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Apalutamide.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Apalutamide.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Apalutamide.Experimental
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Apalutamide.Approved
St. John's WortThe serum concentration of Apalutamide can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be decreased when it is combined with Apalutamide.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be decreased when it is combined with Apalutamide.Experimental
StiripentolThe serum concentration of Apalutamide can be increased when it is combined with Stiripentol.Approved
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Apalutamide.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Apalutamide.Approved
SulfamoxoleThe serum concentration of Sulfamoxole can be decreased when it is combined with Apalutamide.Approved
SulfasalazineThe serum concentration of Sulfasalazine can be decreased when it is combined with Apalutamide.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Apalutamide.Approved
SulfisoxazoleThe serum concentration of Sulfisoxazole can be decreased when it is combined with Apalutamide.Approved, Vet Approved
SumatriptanThe serum concentration of Sumatriptan can be decreased when it is combined with Apalutamide.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Apalutamide.Approved, Investigational
SuprofenThe serum concentration of Suprofen can be decreased when it is combined with Apalutamide.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Apalutamide.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Apalutamide.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Apalutamide.Approved
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Apalutamide.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Apalutamide.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Apalutamide.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Apalutamide.Approved, Investigational
TapentadolThe serum concentration of Tapentadol can be decreased when it is combined with Apalutamide.Approved
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Apalutamide.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Apalutamide.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Apalutamide.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Apalutamide.Experimental
Technetium Tc-99m mebrofeninThe serum concentration of Technetium Tc-99m mebrofenin can be decreased when it is combined with Apalutamide.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Apalutamide.Approved, Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Apalutamide.Approved, Withdrawn
TelithromycinThe serum concentration of Apalutamide can be increased when it is combined with Telithromycin.Approved
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Apalutamide.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Apalutamide.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Apalutamide.Approved
TenoxicamThe serum concentration of Tenoxicam can be decreased when it is combined with Apalutamide.Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Apalutamide.Approved, Withdrawn
TeriflunomideThe serum concentration of Teriflunomide can be decreased when it is combined with Apalutamide.Approved
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Apalutamide.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Apalutamide.Approved, Investigational
Testosterone cypionateThe serum concentration of Testosterone cypionate can be decreased when it is combined with Apalutamide.Approved
Testosterone enanthateThe serum concentration of Testosterone enanthate can be decreased when it is combined with Apalutamide.Approved
Testosterone propionateThe serum concentration of Testosterone propionate can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Testosterone undecanoate can be decreased when it is combined with Apalutamide.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Apalutamide.Approved, Vet Approved
TezacaftorThe serum concentration of Tezacaftor can be decreased when it is combined with Apalutamide.Approved, Investigational
ThalidomideThe serum concentration of Thalidomide can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Apalutamide.Approved
ThiamylalThe serum concentration of Thiamylal can be decreased when it is combined with Apalutamide.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be decreased when it is combined with Apalutamide.Approved, Withdrawn
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Apalutamide.Approved, Investigational
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Apalutamide.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Apalutamide.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Apalutamide.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Apalutamide.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Apalutamide.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Apalutamide.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Apalutamide.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be decreased when it is combined with Apalutamide.Approved, Withdrawn
TocilizumabThe serum concentration of Apalutamide can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe serum concentration of Tocofersolan can be decreased when it is combined with Apalutamide.Approved
TocopherolThe serum concentration of Tocopherol can be decreased when it is combined with Apalutamide.Approved, Investigational
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Apalutamide.Approved, Investigational
TolbutamideThe serum concentration of Tolbutamide can be decreased when it is combined with Apalutamide.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Apalutamide.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Apalutamide.Approved
TopiroxostatThe metabolism of Apalutamide can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Apalutamide.Approved, Investigational
TorasemideThe serum concentration of Torasemide can be decreased when it is combined with Apalutamide.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Apalutamide.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Apalutamide.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Apalutamide.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Apalutamide.Approved, Investigational
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Apalutamide.Approved, Investigational
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Apalutamide.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Apalutamide.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Apalutamide.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Apalutamide.Approved, Investigational
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Apalutamide.Approved
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Apalutamide.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Apalutamide.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Apalutamide.Investigational, Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Apalutamide.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be decreased when it is combined with Apalutamide.Approved, Investigational, Nutraceutical
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Apalutamide.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Apalutamide.Approved
UlobetasolThe serum concentration of Ulobetasol can be decreased when it is combined with Apalutamide.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Apalutamide.Approved
ValbenazineThe serum concentration of Valbenazine can be decreased when it is combined with Apalutamide.Approved, Investigational
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Apalutamide.Approved, Investigational
ValsartanThe serum concentration of Valsartan can be decreased when it is combined with Apalutamide.Approved, Investigational
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Apalutamide.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Apalutamide.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Apalutamide.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Apalutamide.Approved
VelpatasvirThe serum concentration of Velpatasvir can be decreased when it is combined with Apalutamide.Approved, Investigational
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Apalutamide.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Apalutamide.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Apalutamide.Approved
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Apalutamide.Approved
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Apalutamide.Investigational
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Apalutamide.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Apalutamide.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Apalutamide.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Apalutamide.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Apalutamide.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be decreased when it is combined with Apalutamide.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Apalutamide.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Apalutamide.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be decreased when it is combined with Apalutamide.Approved
VoriconazoleThe serum concentration of Apalutamide can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Apalutamide.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be decreased when it is combined with Apalutamide.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Apalutamide.Approved
XimelagatranThe serum concentration of Ximelagatran can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Apalutamide.Approved, Investigational, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Apalutamide.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Apalutamide.Approved, Investigational
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Apalutamide.Approved, Illicit, Investigational
ZaltoprofenThe serum concentration of Zaltoprofen can be decreased when it is combined with Apalutamide.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Apalutamide.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Apalutamide.Approved
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Apalutamide.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Apalutamide.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Apalutamide.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Apalutamide.Approved
ZotepineThe serum concentration of Zotepine can be decreased when it is combined with Apalutamide.Approved, Investigational, Withdrawn
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Apalutamide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE: Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6. [PubMed:27160947]
  2. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH: ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. [PubMed:22266222]
  3. FDA Press Announcements: FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint [Link]
External Links
PubChem Compound
24872560
PubChem Substance
347828234
ChemSpider
28424131
BindingDB
50094975
ChEMBL
CHEMBL3183409
Wikipedia
Apalutamide
FDA label
Download (233 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC)1
1Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer / Metastatic Castration-Resistant Prostate Cancer (mCRPC) / Prostatic Neoplasms1
1Active Not RecruitingTreatmentProstate Cancer1
1Active Not RecruitingTreatmentProstatic Neoplasms, Castration-Resistant2
1CompletedTreatmentHealthy Volunteers3
1RecruitingTreatmentHepatic Impairment1
1RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
1RecruitingTreatmentProstatic Neoplasms1
2Not Yet RecruitingTreatmentAdenocarcinoma of the Prostate / Prostate Cancer1
2Not Yet RecruitingTreatmentAndrogen Antagonists / Neoadjuvant Therapy / Prostate Cancer / Prostatectomy1
2Not Yet RecruitingTreatmentCancer of the Prostate1
2Not Yet RecruitingTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / PSA Progression / Stage IV Prostate Adenocarcinoma AJCC v71
2Not Yet RecruitingTreatmentProstate Cancer4
2Not Yet RecruitingTreatmentProstatic Neoplasms, Castration-Resistant1
2RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC) / Metastatic Castration Resistant Prostate Cancer1
2RecruitingTreatmentDiseases of Male Genital Organs / Prostate Cancer1
2RecruitingTreatmentLow Risk Prostate Cancer1
2RecruitingTreatmentNewly Diagnosed Oligometastatic Prostate Cancer1
2RecruitingTreatmentPSA Progression / Stage III Prostate Adenocarcinoma / Stage IV Prostate Adenocarcinoma1
2RecruitingTreatmentProstate Cancer8
2RecruitingTreatmentStage II Prostate Adenocarcinoma / Stage II Prostate Adenocarcinoma AJCC v71
2RecruitingTreatmentStage III Prostate Adenocarcinoma / Stage III Prostate Adenocarcinoma AJCC v7 / Stage III Prostate Cancer / Stage III Prostate Cancer AJCC v7 / Stage IV Prostate Adenocarcinoma / Stage IV Prostate Adenocarcinoma AJCC v7 / Stage IV Prostate Cancer / Stage IV Prostate Cancer AJCC v71
2WithdrawnTreatmentProstatic Neoplasms, Castration-Resistant1
3Active Not RecruitingTreatmentProstate Cancer1
3Active Not RecruitingTreatmentProstatic Neoplasms2
3RecruitingTreatmentProstate Cancer1
3RecruitingTreatmentProstatic Neoplasms1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral60 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9481663No2013-06-042033-06-04Us
US8802689No2007-03-272027-03-27Us
US8445507No2010-09-152030-09-15Us
US9884054No2013-09-232033-09-23Us
US9388159No2007-03-272027-03-27Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00178 mg/mLALOGPS
logP3.05ALOGPS
logP3.46ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)13.05ChemAxon
pKa (Strongest Basic)-0.75ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area89.33 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity113.6 m3·mol-1ChemAxon
Polarizability43.44 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylimidazolidines. These are polycyclic compounds containing an imidazoline substituted by a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolidines
Sub Class
Imidazolidines
Direct Parent
Phenylimidazolidines
Alternative Parents
2-halobenzoic acids and derivatives / Alpha amino acids and derivatives / N-phenylthioureas / Benzamides / Benzoyl derivatives / Fluorobenzenes / Pyridines and derivatives / Imidazolidinones / Aryl fluorides / Vinylogous halides
show 10 more
Substituents
Phenylimidazolidine / Alpha-amino acid or derivatives / N-phenylthiourea / 2-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / Benzamide / Benzoic acid or derivatives / Benzoyl / Fluorobenzene / Halobenzene
show 29 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH: ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. [PubMed:22266222]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH: ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. [PubMed:22266222]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monovalent cation:proton antiporter activity
Specific Function
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfat...
Gene Name
SLC47A1
Uniprot ID
Q96FL8
Uniprot Name
Multidrug and toxin extrusion protein 1
Molecular Weight
61921.585 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Drug transmembrane transporter activity
Specific Function
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide, metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acy...
Gene Name
SLC47A2
Uniprot ID
Q86VL8
Uniprot Name
Multidrug and toxin extrusion protein 2
Molecular Weight
65083.915 Da

Drug created on October 20, 2016 14:58 / Updated on May 02, 2018 00:12